Clinical Supplies & Commercial Manufacturing Support​

Drug development frequently encounters challenges at the clinical and commercial manufacturing stages. Constraints such as a limited pool of sterile filling suppliers, inconsistent technical maturity among Contract Manufacturing Organisations (CMOs), difficulty filling high-viscosity products, and the lack of scalable manufacturing platforms can delay timelines, increase production costs, and threaten regulatory approval. Complex dosage forms—including ophthalmics, injectables, semisolids, transdermals, and drug–device combination products—demand CMOs with specialised infrastructure, high-containment systems, and proven expertise in global regulatory submissions. Selecting an unsuitable business partner may necessitate repackaging, disrupt supply continuity, and result in suboptimal long-term commercial agreements.

Healios addresses these risks by providing comprehensive technical consulting and CMO identification services for clinical trial supplies and commercial manufacturing. What sets Healios apart is its proprietary, data-driven CMO vetting process that evaluates partners based on both operational capability and proven regulatory track record. The company expedites the CMO selection timeline while maintaining high standards of quality and compliance, enabling sponsors to initiate projects faster and de-risk their supply chain. Healios also distinguishes itself through in-depth process-engineering expertise, Quality by Design (QbD)-driven manufacturability assessments, and robust global regulatory intelligence. The Healios network comprises more than 50 carefully vetted CMOs across the USA, India, Europe, the UK, Canada, Japan, South Korea, Taiwan, China, and the broader Asia-Pacific region, supporting all dosage forms Healios offers. These include topicals, transdermals, ophthalmics, otics, injectables (small- and large-volume parenterals), nasal sprays, implants, inserts, and oral liquids.

Healios identifies advanced CMO capabilities to support complex manufacturing requirements. These include high-containment manufacturing suites for potent and cytotoxic compounds, fully automated aseptic filling lines to reduce contamination risks, and advanced in-line process analytical technology (PAT) for real-time quality control. Additional capabilities within the Healios CMO network comprise isolator technology for sterile processing, modular cleanroom configurations, and digital manufacturing execution systems to ensure traceability and compliance throughout production.

• Flexible batch sizes are available, ranging from grams to tons.
• Advanced processing methods are available, including hot-melt extrusion, cryogenic milling, and additional specialised techniques.
• Fill-finish capabilities encompass ophthalmic gels, long-acting injectables, and emulsions. Development of advanced drug and device combination products is supported through a comprehensive suite of integrated services, which include product development planning, device design, prototyping, precise tooling, assembly, fill-finish processing, and performance qualification. This end-to-end approach ensures that sponsors have clear oversight and support throughout every stage of combination product development.
• Sterilisation services include both aseptic and terminal methods, primarily utilising steam, ethylene oxide (EtO), gamma irradiation, and electron beam technologies.
• Production capabilities extend to hormonal, cytotoxic, potent, and controlled substances.
• Comprehensive packaging and serialisation services are available for a variety of formats, including blow-fill-seal (BFS) vials, pre-filled syringe (PFS) cartridges, and additional configurations.

International logistics, cold-chain management, and clinical supply distribution are conducted in compliance with Good Distribution Practice (GDP) standards.

Healios works with CMOs audited by the US FDA, EMA, MHRA, Health Canada, and PMDA, and is known for strict compliance with global GMP standards. The facilities use strong quality systems, validated equipment trains, strong documentation controls, and proven inspection histories. To proactively mitigate supply and compliance risks, Healios regularly audits all partner CMOs, maintains ongoing performance monitoring, and implements contingency plans to ensure supply continuity in the event of unexpected disruptions. Healios performs comprehensive risk assessments at the outset of each project and follows robust supplier qualification processes. Additionally, periodic reviews of quality and regulatory compliance help anticipate challenges and address them before they impact deliverables. The highly experienced technical and QA teams deliver consistent supply reliability, reproducible batch performance, and regulatory-ready documentation, including master batch records, technology-transfer packages, and CMC modules, enabling an efficient path into global markets.

As part of its long-term growth strategy, Healios is developing an ophthalmic blow-fill-seal (BFS) platform and a sterile injectable large-volume parenteral (LVP) facility in New Jersey, thereby enhancing its capabilities from development through to commercial readiness. The BFS platform is expected to launch in Q4 2025, with the LVP facility anticipated to be operational by Q2 2026. These timelines enable sponsors to plan future projects and ensure timely access to these expanded manufacturing capabilities.